A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglycemia and abdominal obesity.

2006

Effects of Candesartan on Insulin Sensitivity in Non-Diabetic Obese Individuals

Sample size: 100 publication Evidence: moderate

Author Information

Author(s): López-Jaramillo Patricio, Pradilla Lina P, Lahera Vicente, Sieger Federico A Silva, Rueda-Clausen Christian F, Márquez Gustavo A

Primary Institution: Fundación Cardiovascular de Colombia

Hypothesis

Candesartan (32 mg/day during 6 months) has a beneficial effect on fasting plasma glucose, proinflammatory, prothrombotic and oxidative stress markers in non diabetic, non hypertense subjects, with dysglycemia and abdominal obesity.

Conclusion

Candesartan treatment may improve insulin sensitivity and related markers in non-diabetic, non-hypertensive individuals with dysglycemia and abdominal obesity.

Supporting Evidence

The study involved a sample size of 100 subjects to ensure adequate power.
Participants received educational, nutritional, and exercise support during the trial.
Results indicated a potential reduction in insulin resistance markers with Candesartan treatment.

Takeaway

This study looks at whether a medicine called Candesartan can help people who are not diabetic but have high blood sugar and belly fat to use insulin better.

Methodology

A randomized, double blind, cross-over, placebo-controlled clinical trial assessing the effects of Candesartan on various health markers over 6 months.